Abstract Details

Title An Open-Label, 52-Week Extension Study To Assess the Long-Term Tolerability and Efficacy of Gabapentin Enacarbil in Subjects with Moderate-to-Severe Primary Restless Legs Syndrome

Topic Sleep

Presentation(s) (-)

Poster/Presentation
Number 281

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Aaron Ellenbogen, DO	Dr. Ellenbogen has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for allergan. Dr. Ellenbogen has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for allergan. Dr. Ellenbogen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Ellenbogen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Supernus. Dr. Ellenbogen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for ipsen. Dr. Ellenbogen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acorda.
	No disclosure on file
Stephen Thein, PhD (Pacific Research Network)	No disclosure on file
	No disclosure on file
	No disclosure on file
Jerry M. Tolson, PhD (Glaxco Smith Kline)	No disclosure on file
Heather S. Conklin (GlaxoSmithkline)	No disclosure on file
Marie-Liesse Lassauzet, PhD (XenoPort)	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��